The updated guidelines now incorporate ctDNA-MRD assessment as an alternative to biopsy for evaluating PET-positive results at the end of first-line therapy in DLBCL. Specifically, for patients ...
(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), Tuesday announced a partnership with NeoGenomics, Inc. (NEO), an oncology testing services company, to advance minimal residual disease or MRD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback